Subscribe to stay informed!
Berwyn-based Warren Avenue Investors, a real estate firm formed by a former BioMed Realty executive, has established a $365 million venture with Ares Management…
Endo International, the Dublin-based pharmaceutical company with U.S. headquarters in Malvern, reached a $50 million settlement to resolve three opioid cases in New…
Endo International — based in Dublin, Ireland, with a U.S. headquarters in Malvern — has hired a financial restructuring firm to navigate its current legal morass…
Exton-based Recro Pharma has acquired its West Coast competitor, Irisys of San Diego, in a cash and stock deal valued at roughly $50 million…
Endo Health Solutions and Endo Pharmaceuticals — subsidiaries of Endo International, which is based in Dublin, Ireland, and has its U.S. headquarters in Malvern — have…
Malvern-based Galera Therapeutics recently triggered a $37.5 million payment by completing enrollment for a late-stage study of Avasopasem. John George reported on…
Wayne-based Cagent Vascular has received a $9 million investment from Sectoral Asset Management to accelerate the commercialization of its lead product, writes John George…
While even the majority of scientists working on mRNA vaccines for COVID-19 were shocked by its effectiveness, Katalin Karikó, an Abington biochemist and one…
Malvern-based PhaseBio Pharmaceuticals has signed an exclusive licensing agreement valued up to $245 million with Alfasigma of Italy, writes John George for the Philadelphia…
Malvern-based Ocugen has encountered a significant obstacle in its plans to bring the COVID-19 vaccine developed in India to the U.S., writes…
Exton-based Immunome is developing an “antibody cocktail” to fight COVID-19 variants of concern. The World Health Organization and Center for Disease Control classified…
Following Malvern-based Galera Therapeutics providing updated results from early-stage testing of its experimental cancer therapy, the biopharmaceutical company saw its stock surge by…
Berwyn-based Virpax Pharmaceuticals has hired investment bank Torreya Capital to pursue partnering and licensing deals for its experimental pain medicines in global markets, writes…
Before we send you to this site, please subscribe to our daily newsletter.